Solvay Pharma: Dealing Its Way Into the Limelight
Executive Summary
BMS and Wyeth are two of the latest to have noticed Solvay’s unusually healthy pipeline. The mid-sized group’s new dealmaking drive means they’re unlikely to be the last.
You may also be interested in...
Organon Reboots with Biotech
Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.
Organon Reboots with Biotech
Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.